**Appendix B**

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Health Technology Appraisal (MTA)

## Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

## Matrix of consultees and commentators

| **Consultees** | **Commentators (no right to submit or appeal)** |
|---|---|
| Manufacturers/sponsors<br>• Actavis UK (naftidrofuryl oxalate)<br>• Apotex UK (pentoxifylline)<br>• Kent Pharmaceuticals (naftidrofuryl oxalate)<br>• Merck Serono (naftidrofuryl oxalate)<br>• Mylan (inositol nicotinate, naftidrofuryl oxalate)<br>• Otsuka Pharmaceuticals (cilostazol)<br>• Teva (naftidrofuryl oxalate)<br><br>Patient/carer groups<br>• Action Heart<br>• Afiya Trust<br>• AntiCoagulation Europe (ACE)<br>• Black Health Agency<br>• Blood Pressure Association<br>• Chinese National Healthy Living Centre<br>• Counsel and Care<br>• Equalities National Council<br>• Lifeblood: The Thrombosis Charity<br>• Muslim Council of Great Britain<br>• Muslim Health Network<br>• South Asian Health Foundation<br>• Specialised Healthcare Alliance<br><br>Professional groups<br>• Association of Surgeons of Great Britain and Ireland<br>• British Association for Nursing in Cardiac Care<br>• British Association for Service to the Elderly | General<br>• Board of Community Health Councils in Wales<br>• British Cardiovascular Industry Association<br>• British National Formulary<br>• Commissioning Support Appraisals Service<br>• Department of Health, Social Services and Public Safety for Northern Ireland<br>• Medicines and Healthcare products Regulatory Agency<br>• National Association of Primary Care<br>• NHS Alliance<br>• NHS Commercial Medicines Unit<br>• NHS Confederation<br>• NHS Quality Improvement Scotland<br>• Public Health Wales NHS Trust<br>• Scottish Medicines Consortium<br><br>Possible comparator manufacturers<br>• None<br><br>Relevant research groups<br>• British Society for Cardiovascular Research - BCS affiliated<br>• Cardiovascular Diseases Specialist Library (CVDSL)<br>• Central Cardiac Audit Database<br>• Cochrane Heart Group<br>• MRC Clinical Trials Unit<br>• National Institute for Health Research<br>• Policy Research Institute on Ageing and Ethnicity |

**Appendix B**

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| • British Cardiovascular Intervention Society (BCIS)<br>• British Cardiovascular Society<br>• British Geriatrics Society<br>• British Heart Foundation<br>• British Institute of Radiology (BIR)<br>• British Society of Cardiac Radiologists<br>• British Society of Interventional Radiology (BSIR)<br>• Chartered Society of Physiotherapy (CSP)<br>• National Heart Forum (UK)<br>• Physiotherapy Pain Association<br>• Primary Care Cardiovascular Society<br>• Radiological Research Trust, the<br>• Royal College of Anaesthetists<br>• Royal College of General Practitioners<br>• Royal College of Nursing<br>• Royal College of Pathologists<br>• Royal College of Physicians<br>• Royal College of Radiologists Breast Group<br>• Royal College of Surgeons<br>• Royal Pharmaceutical Society<br>• Royal Society of Medicine – Intellectual Disabilities Forum<br>• Society for Cardiological Science & Technology<br>• United Kingdom Clinical Pharmacy Association<br><br><u>Others</u><br>• Department of Health<br>• NHS Luton<br>• NHS Salford<br>• Welsh Assembly Government | • Research Institute for the Care of Older People<br>• Wellcome Trust - Cardiovascular Research Initiative<br><br><u>Assessment Group</u><br>• National Institute for Health Research Health Technology Assessment Programme<br>• School of Health & Related Research Sheffield<br><br><u>Associated Guideline Groups</u><br>• National Clinical Guidelines Centre<br><br><u>Associated Public Health Groups</u><br>• None |

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).